The FDA on Friday approved Afluria, a vaccine developed by Australian drugmaker CSL Ltd. to protect people ages 18 and older from type A and B influenza viruses. CSL is poised to supply 2 million doses of Afluria to the U.S. market for the coming flu season.

Full Story:

Related Summaries